12/12
12:50 pm
apvo
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
High
Report
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
12/12
09:25 am
apvo
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial [Yahoo! Finance]
High
Report
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial [Yahoo! Finance]
12/12
09:00 am
apvo
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
High
Report
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
12/9
02:02 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
12/1
03:05 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/29
09:55 am
apvo
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
High
Report
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
11/26
08:48 am
apvo
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation [Yahoo! Finance]
Low
Report
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation [Yahoo! Finance]
11/26
08:35 am
apvo
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Medium
Report
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
11/23
03:33 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/22
08:53 am
apvo
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm [Yahoo! Finance]
Medium
Report
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm [Yahoo! Finance]
11/22
08:35 am
apvo
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
High
Report
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
11/20
08:57 am
apvo
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies [Yahoo! Finance]
Medium
Report
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies [Yahoo! Finance]
11/20
08:35 am
apvo
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Medium
Report
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
11/15
03:08 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/11
08:20 am
apvo
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial [Yahoo! Finance]
Medium
Report
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial [Yahoo! Finance]
11/11
08:05 am
apvo
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
High
Report
First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial
11/7
08:05 am
apvo
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
High
Report
Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update
11/7
02:04 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/30
02:07 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/29
08:05 am
apvo
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
High
Report
Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024
10/24
02:42 am
apvo
Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update [Yahoo! Finance]
Medium
Report
Alligator Bioscience AB Reports Financial Results for the First 9 Months of 2024 and for Q3 2024 and Provides a Business Update [Yahoo! Finance]
10/22
02:02 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/14
02:18 am
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
10/6
08:09 pm
apvo
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Aptevo Therapeutics Inc. (NASDAQ: APVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.